Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Opiant receives FDA feedback on development of OPNT-002 for alcohol use disorder

March 2, 2017

Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150

Feb. 23, 2017

FDA issues complete response letter for Amphastar's intranasal naloxone

Feb. 23, 2017

Adapt Pharma applies for E.U. approval of naloxone HCl nasal spray

Feb. 22, 2017

Amygdala Neurosciences acquires ALDH2 inhibitor from Gilead

Feb. 17, 2017

Chrysalis Biotherapeutics begins contract with NIAID for TP-508 as nuclear countermeasure

Feb. 9, 2017

GSK-598809 restores reward deficits in substance dependence

Jan. 18, 2017

TSRI, Icahn School of Medicine and UPenn patent nAChR modulators

Dec. 15, 2016

Promising phase III topline results for CAM-2038 to treat moderate to severe opioid use disorder

Nov. 14, 2016

Omeros reports on phase II trial of PPARgamma agonist in heroin-dependent subjects

Nov. 3, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Asia
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Capital remains selective in ‘barbell’ biotech market
BioWorld Asia
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...